RxDoctor Payments Data

Gloria Piedra

Internal Medicine · Hialeah, FLNPI 1467410431

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 49 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$506
  • Novo Nordisk$160
  • Amgen$123
  • Sanofi-aventis U.S. LLC$71
  • Boehringer Ingelheim$57
  • GSK$53
  • plus $80 from 3 others

What the payments were for

  • Food & beverage$1,04099%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$4,679
Medicare patients
15
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$112,247
MounjaroTirzepatide91$109,082
JardianceEmpagliflozin88$89,439
FarxigaDapagliflozin Propanediol74$81,411
TrulicityDulaglutide28$47,989
XareltoRivaroxaban39$37,552
OzempicSemaglutide27$34,602
EntrestoSacubitril/Valsartan13$22,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,544
TradjentaLinagliptin14$11,483
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$6,489
PremarinEstrogens, Conjugated12$6,164
Atrovent HfaIpratropium Bromide12$5,566
SymbicortBudesonide/Formoterol Fumarate16$5,436
LantusInsulin Glargine,hum.Rec.Anlog43$4,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$506$158,949138 claims
Boehringer IngelheimJardiance, Tradjenta$57$100,922102 claims
Novo NordiskOzempic$160$34,60227 claims
NovartisEntresto$9$22,16513 claims
GSKTrelegy Ellipta$53$21,54424 claims
AbbVieSynthroid, Lumigan$51$7,49059 claims
Sanofi-aventis U.S. LLCLantus$71$4,92543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →